Skip to main content
Premium Trial:

Request an Annual Quote

Q4 Revenues up, but Losses Widen for Exelixis

NEW YORK, Feb. 17 (GenomeWeb News) - Exelixis today reported an increase in revenues for the quarter ended Dec. 31, 2003, along with higher net losses and rising R&D expenses.

Exelixis posted total revenues of $13.8 million for the fourth quarter, up from $12.5 million in the same period of 2002.

The company's net loss widened to $23.3 million from $20.9 million in the fourth quarter of 2002.

R&D expenses for the quarter were $32.6 million, compared to $27.7 million for the equivalent period of 2002. Exelixis said the increase in R&D spending was due to its expanded drug discovery and development operations and clinical and preclinical development programs.

As of Dec. 31, 2003, the company's cash, cash equivalents, short-term investments, and restricted cash totaled $241.9 million, compared to $222.0 million at the end of 2002.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.